Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Lantern Pharma ( (LTRN) ).
Lantern Pharma reported its third quarter 2025 financial results and business updates, highlighting significant progress in clinical validation, regulatory advancements, and strategic momentum. The company achieved all primary endpoints in its LP-184 Phase 1a clinical trial, showing a 48% clinical benefit rate in cancer patients, and received FDA guidance for its pediatric CNS cancer trial. The AI platform’s commercial readiness was demonstrated, and disciplined capital management was maintained, positioning Lantern Pharma for future growth in oncology indications.
The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company that utilizes its proprietary RADR® artificial intelligence and machine learning platform to enhance oncology drug discovery and development. The company focuses on developing AI-driven drug candidates and advancing precision medicine approaches in oncology.
Average Trading Volume: 130,531
Technical Sentiment Signal: Strong Sell
Current Market Cap: $37.58M
For detailed information about LTRN stock, go to TipRanks’ Stock Analysis page.